Search
Research
Haemophilus influenzae remains the predominant otitis media pathogen in Australian children undergoing ventilation tube insertion in the PCV13 eraUnderstanding patterns of bacterial carriage and otitis media (OM) microbiology is crucial for assessing vaccine impact and informing policy. The microbiology of OM can vary with geography, time, and interventions like pneumococcal conjugate vaccines (PCVs). We evaluated the microbiology of nasopharyngeal and middle ear effusions in children living in Western Australia, 11 years following the introduction of PCV13.
Research
Dornase alfa as an adjunct therapy to treat chronic ear infectionsChris Glenn Lea-Ann Peter Ruth Brennan-Jones Pearson Kirkham Richmond Thornton PhD BA (Education) PhD Candidate PhD MBBS MRCP(UK) FRACP PhD Head, Ear
Research
Evaluation of a bacterial therapy for prevention of respiratory infection including influenza and otitis mediaDeborah Lea-Ann Peter Ruth Strickland Kirkham Richmond Thornton PhD PhD MBBS MRCP(UK) FRACP PhD Head, Pregnancy and Early Life Immunology Co-Head,
Research
Microbiological and immunological factors predicting surgical outcomes for chronic otitis mediaLea-Ann Peter Ruth Kirkham Richmond Thornton PhD MBBS MRCP(UK) FRACP PhD Co-Head, Bacterial Respiratory Infectious Disease Group; Microbiology Lead,
Research
Pathogens on the rise: is impaired immunity the cause of chronic ear and chest infections?Ruth Elke Peter Thornton Seppanen Richmond PhD BSc PhD MBBS MRCP(UK) FRACP Co-head, Bacterial Respiratory Infectious Disease Group (BRIDG) Program
Research
Differences in Pneumococcal and Haemophilus influenzae Natural Antibody Development in Papua New Guinean Children in the First Year of LifeDevelopment of vaccines to prevent disease and death from Streptococcus pneumoniae, and nontypeable Haemophilus influenzae (NTHi), the main pathogens that cause otitis media, pneumonia, meningitis and sepsis, are a global priority.
Research
PCV10 elicits Protein D IgG responses in Papua New Guinean children but has no impact on NTHi carriage in the first two years of lifeNasopharyngeal colonisation with nontypeable Haemophilus influenzae (NTHi) is associated with development of infections including pneumonia and otitis media. The 10-valent pneumococcal conjugate vaccine (PCV10) uses NTHi Protein D (PD) as a carrier. Papua New Guinean children have exceptionally early and dense NTHi carriage, and high rates of NTHi-associated disease.
Research
A systems biology approach to determining the risk for development of otitis mediaPeter Ruth Elke Richmond Thornton Seppanen MBBS MRCP(UK) FRACP PhD BSc PhD Head, Vaccine Trials Group Co-head, Bacterial Respiratory Infectious
People
Associate Professor Lea-Ann KirkhamCo-Head, Bacterial Respiratory Infectious Disease Group; Microbiology Lead, Wesfarmers Centre of Vaccines & Infectious Diseases
Research
The Platform Trial In COVID-19 priming and BOOsting : The immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2PICOBOO is a randomised, adaptive trial evaluating the immunogenicity, reactogenicity, and safety of COVID-19 booster strategies. Here, we present data for second boosters among individuals aged 18-<50 and 50-<70 years old primed with BNT162b2 until Day (D) 84.